Jump to the top of the page

Showing 840 – 850 of 1303 results

  • NDC and Platinum Equity Transaction

    William Blair acted as financial advisor to NDC, Inc., a portfolio company of Court Square Capital Partners, in connection with its sale to Platinum Equity.

  • Mill Rock Capital and The ExecuSearch Group Transaction

    William Blair acted as exclusive M&A advisor to Mill Rock Capital in connection with the acquisition of The Execu|Search Group (TESG), a portfolio company of New Heritage Capital.

  • Secular Trends Driving Emerging Markets Growth

    The landscape for emerging markets is changing. How are these markets evolving? What are the key secular growth trends? And which markets should investors focus on?

  • Samsara Inc. Initiation

    William Blair initiated research coverage of Samsara Inc. (IOT $22.99). Samsara helps companies digitize their physical operations through its connected operations cloud, which ingests internet of things (IoT) data and provides actionable insights.

  • The Beauty Health Company Initiation

    William Blair initiated research coverage of The Beauty Health Company (SKIN $21.64). The company is a market leader in beauty health through its core asset, HydraFacial.

  • Elastic NV Initiation

    William Blair initiated research coverage of Elastic N.V. (ESTC $82.73), a provider of observability, enterprise search, and security solutions.

  • AbbVie Inc Initiation of Research Coverage

    William Blair initiated research coverage of AbbVie Inc. (ABBV $143.74).

  • Definitive Healthcare Corp Initiation

    William Blair initiated research coverage of Definitive Healthcare Corp. (DH $10.99), a leading provider of healthcare commercial intelligence data and analytics solutions.

  • Adobe Inc Initiation

    William Blair initiated research coverage of Adobe Inc. (ADBE $344.54), a leading enterprise software business that caters its solutions toward creative professionals, communicators, and marketers.

  • Adaptive Biotechnologies Corporation Initiation

    William Blair & Company initiated research coverage of Adaptive Biotechnologies Corporation (ADPT $38.01). Adaptive seeks to improve people’s lives by translating the scale and precision of its adaptive immune systems into products to help diagnose, treat, and monitor disease.

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures